These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14402588)

  • 21. [ANTICOAGULANTS. 2. HEPARINS, HAPARINOIDS, RARE EARTHS AND THROMBOLYTICS].
    REPPEL L
    Pharmazie; 1964 Mar; 19():189-96. PubMed ID: 14248782
    [No Abstract]   [Full Text] [Related]  

  • 22. THE EFFECT OF HEPARIN, HEPARINOIDS, AND OTHER ELECTRONEGATIVE COMPOUNDS ON THE IN VITRO THROMBIN-FIBRINOGEN CONVERSION AND ON WHOLE BLOOD CLOTTING TIME.
    SALAFSKY B; LOOMIS TA
    Arch Int Pharmacodyn Ther; 1964 Jul; 150():107-17. PubMed ID: 14204484
    [No Abstract]   [Full Text] [Related]  

  • 23. [Metachromatic dyes and heparinoids: mechanism of action on blood coagulation and on the fertilization membrane of sea urchin eggs].
    MOLHO D; MOLHO-LACROIX L
    C R Seances Soc Biol Fil; 1955 May; 149(9-10):956-60. PubMed ID: 13270487
    [No Abstract]   [Full Text] [Related]  

  • 24. ASSAY OF BLOOD COAGULATION FACTORS IN HEPARINIZED BLOOD.
    PERKINS HA; ROLFS MR; TORG B
    Thromb Diath Haemorrh; 1964 Apr; 11():254-66. PubMed ID: 14167110
    [No Abstract]   [Full Text] [Related]  

  • 25. [On the isolation of a fraction of serum lipoproteins after precipitation by heparin or by synthetic heparinoids].
    Burstein M
    C R Hebd Seances Acad Sci; 1956 Jul; 243(5):527-9. PubMed ID: 13365134
    [No Abstract]   [Full Text] [Related]  

  • 26. [HEPARINOIDS--PHYSIOLOGICAL PROPERTIES AND THERAPEUTIC INDICATIONS].
    GUILLEMAN P; HARDY N
    Rev Prat; 1964 Oct; 14():3391-405. PubMed ID: 14205831
    [No Abstract]   [Full Text] [Related]  

  • 27. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
    Gantioqui J; Stevic I; Atkinson H; Chan AKC
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes.
    Rops AL; Jacobs CW; Linssen PC; Boezeman JB; Lensen JF; Wijnhoven TJ; van den Heuvel LP; van Kuppevelt TH; van der Vlag J; Berden JH
    Nephrol Dial Transplant; 2007 Apr; 22(4):1070-7. PubMed ID: 17255131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anticoagulant medication. II. Heparin and synthetic heparinoids].
    RICHON J; LECONTE DES FLORIS R
    Concours Med; 1960 Oct; 82():4377-82. PubMed ID: 13741363
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On the anti-heparinic action of some synthetic heparinoids].
    Burstein M; Guinand A
    Sang; 1956; 27(6):558-64. PubMed ID: 13390773
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacology of Heparin and Related Drugs.
    Mulloy B; Hogwood J; Gray E; Lever R; Page CP
    Pharmacol Rev; 2016 Jan; 68(1):76-141. PubMed ID: 26672027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [RESEARCH ON THE ANTIHEPARIN ACTIVITY OF PHOSPHOLIPIDS. II. ACTION OF PLATELETS AND THEIR PHOSPHOLIPID SUBSTITUTES ON PROACCELERIN INHIBITION BY HEPARIN].
    ASCARI E; BARBIERI U; GOBBI F
    Prog Med (Napoli); 1964 Sep; 20():580-3. PubMed ID: 14258160
    [No Abstract]   [Full Text] [Related]  

  • 34. [Research on the mechanism of action of pcmaccelerin (factor V, labile factor). III. Inhibition of proaccelerin by heparin].
    GOBBI F; ASCARI E; BARBIERI U
    Prog Med (Napoli); 1961 Nov; 17():767-76. PubMed ID: 13899354
    [No Abstract]   [Full Text] [Related]  

  • 35. [Basic principles anticoagulant therapy].
    Mammen EF
    Internist (Berl); 1969 Jan; 10(1):2-8. PubMed ID: 4190310
    [No Abstract]   [Full Text] [Related]  

  • 36. [Relations between hyaluronidase inhibition and anticoagulant activity of heparins and heparinoids].
    VAN CANEGHEM P; MARX R; SPIER HW
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1955; 227(2):149-60. PubMed ID: 13309407
    [No Abstract]   [Full Text] [Related]  

  • 37. EFFECTS OF FIBRINOLYTIC AGENTS AND HEPARIN ON BLOOD COAGULATION IN DOGS.
    LEWIS JH; SHIRAKAWA M
    Am J Physiol; 1964 Nov; 207():1049-52. PubMed ID: 14237448
    [No Abstract]   [Full Text] [Related]  

  • 38. [On the behavior of the plasma "clearing factor" after the administration of a synthetic heparinoid].
    CAMERADA P; CONGIU M; LEO P
    Boll Soc Ital Biol Sper; 1959 Nov; 35():1498-9. PubMed ID: 13807122
    [No Abstract]   [Full Text] [Related]  

  • 39. [The increase of thrombin inhibitor in the blood after percutaneous administration of a heparinoid].
    WITTE S; BRESSEL D
    Klin Wochenschr; 1960 May; 38():501. PubMed ID: 13845470
    [No Abstract]   [Full Text] [Related]  

  • 40. [Indications and clinical application of thrombosis prophylaxis. I].
    Mittelkötter U; Reith HB; Thiede A
    Zentralbl Chir; 2000; 125(7):W49-52. PubMed ID: 10960979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.